Biocytogen
Dr. Chen Zhaorong has been a deputy general manager. He has also been the chief medical officer of Eucure (Beijing) since June 2021. Dr. Chen was the representative of Sanofi China and the vice president of GlaxoSmithKline China. He also worked as the chief medical officer of CASI Pharmaceuticals, Inc, a biopharmaceuticals company listed on NASDAQ (stock code: CASI). From November 2016 to December 2017, he served as the chief medical officer of Phagelux (Nanjing) Biotechnology Co., Ltd. He was also the chief medical officer of Chime Biologics (Wuhan) Co., Ltd, formerly known as Xikang (Wuhan) Biopharmaceutical Co., Ltd., from January 2018 to January 2020, and Shanghai Langyu Health Technology (Group) Co., Ltd. Dr. Chen obtained a bachelor’s degree in medicine in August 1983 and a master’s degree in pharmacology in October 1985 from Shandong Medical University (formerly known as Shandong Medical College) in the PRC. In May 1989, he obtained a doctorate degree in philosophy from the University of Adelaide in Australia.
This person is not in any teams
This person is not in any offices
Biocytogen
2 followers
Biocytogen is a preclinical stage biotech that provides a one-stop solution for antibody discovery from target to IND application. With cutting-edge technologies, state-of-art animal facility, and world-class platforms for antibody drug discovery, Biocytogen offers animal model generation, antibody fully human-mouse (RenMab mouse), therapeutic antibody discovery and development, in vivo/in vitro preclinical studies, CMC/CDMO, and regulatory affairs support.